<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686205</url>
  </required_header>
  <id_info>
    <org_study_id>7B5-02-05R05</org_study_id>
    <nct_id>NCT00686205</nct_id>
  </id_info>
  <brief_title>Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Diagnostics Division</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Diagnostics Division</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test blood samples from volunteer donors of whole blood and blood components using a new
      investigational test that detects human immunodeficiency virus (HIV) infection. Results will
      be compared to the current HIV screening assay.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PRISM HIV O Plus Test Data for Specificity</measure>
    <time_frame>12 months</time_frame>
    <description>Negative HIV status was determined by the results of the HIV-1/HIV-2 comparator assay and HIV-1 qualitatitve RNA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PRISM HIV O Plus Test Data for Sensitivity</measure>
    <time_frame>12 months</time_frame>
    <description>Final HIV status was determined according to a supplemental testing algorithm for specimens positive by the investigational assay. Supplemental testing involved HIV-1 Western blot, HIV-2 EIA, HIV-2 Western blot and HIV-1 ribonucleic acid (RNA).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24111</enrollment>
  <condition>Healthy Donors</condition>
  <condition>HIV Positive</condition>
  <arm_group>
    <arm_group_label>ABBOTT PRISM HIV O Plus assay for Specificity</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will have their blood tested by the investigational HIV test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABBOTT PRISM HIV O Plus Assay for Sensitivity</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Samples collected from specimen vendors or from specimen collection studies were tested by the investigational HIV assay.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>collection of follow-up sample based on PRISM HIV O Plus result</intervention_name>
    <description>Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.</description>
    <arm_group_label>ABBOTT PRISM HIV O Plus assay for Specificity</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy donors that have consented to study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mississippi Valley Regional Blood Center</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Blood Center of Greater Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Blood Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Red Cross</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interstate Blood Bank, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Blood And Tissue Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound Blood Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <results_first_submitted>January 13, 2010</results_first_submitted>
  <results_first_submitted_qc>June 4, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 5, 2010</results_first_posted>
  <last_update_submitted>December 16, 2011</last_update_submitted>
  <last_update_submitted_qc>December 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy donors</keyword>
  <keyword>HIV positives</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>21606 donors enrolled from 6 geographically distinct blood donor and 1 plasmapheresis center. All donors were eligible if they signed a study consent form.
In addition, 1388 specimens positive for HIV antibodies and 1117 specimens from US individuals at increased risk of HIV infection or from an HIV-2 endemic area.</recruitment_details>
      <pre_assignment_details>All subjects were assigned to one group. There was no pre-screening criteria specific for this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ABBOTT PRISM® HIV O Plus Assay Results for Specificity</title>
          <description>Blood specimens collected from donors were tested by the investigational HIV test.</description>
        </group>
        <group group_id="P2">
          <title>ABBOTT PRISM® HIV O Plus Assay Results for Sensitivity</title>
          <description>Samples collected from specimen vendors or from specimen collection studies were tested by the investigational HIV assay.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21606"/>
                <participants group_id="P2" count="2505"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15599"/>
                <participants group_id="P2" count="1524"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6007"/>
                <participants group_id="P2" count="981"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Specimen handling procedure altered</title>
              <participants_list>
                <participants group_id="P1" count="5878"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Specimens not confirmed HIV positive</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="981"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ABBOTT PRISM® HIV O Plus Assay Results for Specificity</title>
          <description>Blood specimens collected from donors were tested by the investigational HIV test.</description>
        </group>
        <group group_id="B2">
          <title>ABBOTT PRISM® HIV O Plus Assay Results for Sensitivity</title>
          <description>Samples collected from specimen vendors or from specimen collection studies were tested by the investigational HIV assay.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21606"/>
            <count group_id="B2" value="2505"/>
            <count group_id="B3" value="24111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;= 17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21606"/>
                    <measurement group_id="B2" value="2454"/>
                    <measurement group_id="B3" value="24060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>not collected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1683"/>
                    <measurement group_id="B3" value="1683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="441"/>
                    <measurement group_id="B3" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Collected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21606"/>
                    <measurement group_id="B2" value="381"/>
                    <measurement group_id="B3" value="21987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21606"/>
                    <measurement group_id="B2" value="1614"/>
                    <measurement group_id="B3" value="23220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Côte D'Ivoire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="840"/>
                    <measurement group_id="B3" value="840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cameroon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PRISM HIV O Plus Test Data for Specificity</title>
        <description>Negative HIV status was determined by the results of the HIV-1/HIV-2 comparator assay and HIV-1 qualitatitve RNA.</description>
        <time_frame>12 months</time_frame>
        <population>The analysis was per the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV Negative Donors</title>
            <description>Donors with HIV-1/2 negative results using reference test and negative by HIV-1 RNA test</description>
          </group>
        </group_list>
        <measure>
          <title>PRISM HIV O Plus Test Data for Specificity</title>
          <description>Negative HIV status was determined by the results of the HIV-1/HIV-2 comparator assay and HIV-1 qualitatitve RNA.</description>
          <population>The analysis was per the protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15599"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PRISM HIV O Plus reactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRISM HIV O Plus nonreactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15589"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Clinical Specificity</param_type>
            <param_value>99.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>99.88</ci_lower_limit>
            <ci_upper_limit>99.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PRISM HIV O Plus Test Data for Sensitivity</title>
        <description>Final HIV status was determined according to a supplemental testing algorithm for specimens positive by the investigational assay. Supplemental testing involved HIV-1 Western blot, HIV-2 EIA, HIV-2 Western blot and HIV-1 ribonucleic acid (RNA).</description>
        <time_frame>12 months</time_frame>
        <population>1,388 specimens from individuals positive for HIV antibodies and 136 specimens positive by supplemental testing from US individuals at increased risk of HIV infection or from an HIV-2 endemic area. These 1,524 specimens were used for the sensitivity calculation.</population>
        <group_list>
          <group group_id="O1">
            <title>HIV Positive Samples</title>
            <description>Known HIV-1 or HIV-2 positive samples were used. Samples were determined to be positive by HIV-1 or HIV-2 western blot.</description>
          </group>
        </group_list>
        <measure>
          <title>PRISM HIV O Plus Test Data for Sensitivity</title>
          <description>Final HIV status was determined according to a supplemental testing algorithm for specimens positive by the investigational assay. Supplemental testing involved HIV-1 Western blot, HIV-2 EIA, HIV-2 Western blot and HIV-1 ribonucleic acid (RNA).</description>
          <population>1,388 specimens from individuals positive for HIV antibodies and 136 specimens positive by supplemental testing from US individuals at increased risk of HIV infection or from an HIV-2 endemic area. These 1,524 specimens were used for the sensitivity calculation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1524"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PRISM HIV O Plus reactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRISM HIV O Plus nonreactive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Clinical Sensitivity</param_type>
            <param_value>100.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>99.76</ci_lower_limit>
            <ci_upper_limit>100.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subject related adverse events related to blood collection of the 19 follow-up specimens - 8/23/07 to 8/12/08.</time_frame>
      <desc>Adverse event reporting was only applicable to the 19 donors that returned for follow-up specimen collection. Adverse event reporting does not apply to the donor specimens collected as part of the routine donation or for the specimens used for sensitivity provided by Abbott.
There were no device adverse events associated with testing.</desc>
      <group_list>
        <group group_id="E1">
          <title>ABBOTT PRISM® HIV O Plus Assay Results for Specificity</title>
          <description>Blood specimens collected from donors were tested by the investigational HIV test.</description>
        </group>
        <group group_id="E2">
          <title>ABBOTT PRISM® HIV O Plus Assay Results for Sensitivity</title>
          <description>Samples collected from specimen vendors or from specimen collection studies were tested by the investigational HIV assay.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI must provide a copy of any proposed publication or presentation at least 30 days prior to submission for sponsor's review/approval. The PI must incorporate changes as the sponsor requires in order to protect the sponsor's proprietary rights and interests. The sponsor may require the PI to include acknowledgement of the sponsor's role in the study. The PI may be requested to delay publication/presentation an extra 60 days to enable sponsor to secure patent or other proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peggy Moreno</name_or_title>
      <organization>Abbott Diagnostics Division</organization>
      <phone>847-937-2044</phone>
      <email>Peggy.Moreno@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

